Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study

Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study

Introduction: A common treatment for localized prostate cancer (PCa) is radiotherapy; however, effectiveness is hampered because of toxicities and tumor resistance. Cyclooxygenase-2 (COX-2) inhibitors have been identified as potential agents that could improve treatment outcomes and have demonstrate...

Full description

Bibliographic Details
Main Authors:	Liam King, David Christie, Devinder Arora, Shailendra Anoopkumar-Dukie
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Prostate International
Online Access:	http://www.sciencedirect.com/science/article/pii/S2287888219300807

Similar Items

Drivers of Radioresistance in Prostate Cancer
by: Liam King, et al.
Published: (2022-09-01)

Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
by: Law, A, et al.
Published: (2007)

Protection against Radiotherapy-Induced Toxicity
by: Susan Hall, et al.
Published: (2016-07-01)

Effect of urinary retention on the levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostatic disease
by: R Chawla, et al.
Published: (2003-01-01)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
by: , DAHESIHDEWI, Andaru, et al.
Published: (2002)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
by: Hyungseok Cho, et al.
Published: (2022-03-01)

Prognostic significance of Prostate-Specific Antigen (PSA) rate of change in patients with advanced prostate cancer
by: A E Aghaji, et al.
Published: (2005-01-01)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Prostate Specific Antigen (PSA) testing practices in an academic healthcare organization
by: Margarita Echeverri, et al.
Published: (2022-03-01)

Pengaruh kateterisasi terhadap hasil penetapan prostate specific antigen (PSA) pada pasien gangguan prostat
by: Perpustakaan UGM, i-lib
Published: (2005)

Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction
by: Simona Ferraro, et al.
Published: (2021-07-01)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
by: Narisa Dewi Maulany Darwis, et al.
Published: (2020-08-01)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
by: Naseruddin Höti, et al.
Published: (2023-02-01)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
by: Fernando López-Campos, et al.
Published: (2021-11-01)

Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
by: Koji Yoshimura, et al.
Published: (2022-07-01)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
by: Roddam, A, et al.
Published: (2005)

Erratum: Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level (British Journal of Urology International 87 (638-642))
by: Törnblom, M, et al.
Published: (2001)

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
by: Nikita Sushentsev, et al.
Published: (2023-06-01)

Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy
by: Nina Čamdžić, et al.
Published: (2021-02-01)

Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
by: Narisa Dewi Maulany Darwis, et al.
Published: (2020-03-01)

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma
by: Josephine Kersting, et al.
Published: (2023-07-01)

SIRT1 and SIRT2 Modulators: Potential Anti-Inflammatory Treatment for Depression?
by: Yuqing Zhang, et al.
Published: (2021-02-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
by: Minoru Kobayashi, et al.
Published: (2023-03-01)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
by: Végvári, A, et al.
Published: (2010)

Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research
by: Littlejohns, T, et al.
Published: (2016)

Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era
by: Patrick W. McLaughlin, et al.
Published: (2024-03-01)

Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?
by: Mari Carmen Bernal-Soriano, et al.
Published: (2021-06-01)

Diagnostic value of free-to-total PSA proportion and PSA density in prostate cancer detection for prostate volumes >= 100 cc
by: Murat Zor, et al.
Published: (2018-12-01)